SLC5A2 and heart failure: SGLT2 inhibitors display the greatest beneficial effect on heart failure and progression of renal disease, and have only modest beneficial effects on reducing atherosclerotic CVD, and primarily are effective in patients with established atherosclerotic disease (162).